Is Diamondback Energy a Good Stock to Buy?
Diamondback Energy (FANG) is a lesser-known diamond in the rough…
Sell
16
SKIN Quote, Financials, Valuation and Earnings
Last price:
$1.34
Seasonality move
:
-12.08%
Day range:
$1.33 - $1.40
52-week range:
$0.91 - $4.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.58x
P/B ratio:
3.41x
Volume:
355.6K
Avg. volume:
666.6K
1-year change:
-69.2%
Market cap:
$176.6M
Revenue:
$334.3M
EPS (TTM):
-$0.43
Analysts' Opinion
-
Consensus RatingThe Beauty Health has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.58, The Beauty Health has an estimated upside of 11.7% from its current price of $1.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $1.34.
Fair Value
-
According to the consensus of 7 analysts, The Beauty Health has 11.7% upside to fair value with a price target of $1.58 per share.
SKIN vs. S&P 500
-
Over the past 5 trading days, The Beauty Health has overperformed the S&P 500 by 7.99% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
The Beauty Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
The Beauty Health revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter The Beauty Health reported revenues of $83.5M.
Earnings Growth
-
The Beauty Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter The Beauty Health reported earnings per share of -$0.08.
Enterprise value:
358.7M
EV / Invested capital:
0.59x
Price / LTM sales:
0.58x
EV / EBIT:
--
EV / Revenue:
1.07x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
38.41x
Price / Operating cash flow:
20.85x
Enterprise value / EBITDA:
24.67x
Gross Profit (TTM):
$182.3M
Return On Assets:
-3.76%
Net Income Margin (TTM):
-8.7%
Return On Equity:
-47.95%
Return On Invested Capital:
-4.33%
Operating Margin:
-8.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $365.9M | $398M | $334.3M | $96.8M | $83.5M | |
| Gross Profit | $248.8M | $155.1M | $182.3M | $45.7M | $52.3M | |
| Operating Income | -$25.8M | -$130.9M | -$67.8M | -$18.4M | -$7.2M | |
| EBITDA | $81.6M | -$53.6M | $14.5M | $4.5M | -$2.7M | |
| Diluted EPS | -$0.19 | -$0.76 | -$0.43 | -$0.08 | -$0.08 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $59.1M | $1B | $783.3M | $698.3M | $477.1M | |
| Total Assets | $222.8M | $1.2B | $1B | $929.1M | $685.7M | |
| Current Liabilities | $30.9M | $76.4M | $71.7M | $115M | $68.2M | |
| Total Liabilities | $252.8M | $916.5M | $836M | $869.7M | $633.9M | |
| Total Equity | -$30M | $302.3M | $167.1M | $59.4M | $51.8M | |
| Total Debt | $216.5M | $729.9M | $734.1M | $738.4M | $552.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$106.6M | $21.8M | $16.1M | -$5.2M | $16.5M | |
| Cash From Investing | -$18.9M | -$31.5M | -$6.8M | -$2.2M | -$862K | |
| Cash From Financing | -$205.2M | -$37.4M | -$158.3M | -$31.4M | -$770K | |
| Free Cash Flow | -$124M | $8.7M | $9.3M | -$7.3M | $15.6M | |
SKIN
Sector
Market Cap
$176.6M
$282.5M
Price % of 52-Week High
30.52%
72.58%
Dividend Yield
0%
0%
Shareholder Yield
--
3.03%
1-Year Price Total Return
-65.69%
-12.27%
Beta (5-Year)
--
0.460
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.34
200-day SMA
Sell
Level
$1.62
Bollinger Bands (100)
Sell
Level
1.4 - 1.7
Chaikin Money Flow
Sell
Level
-48.6M
20-day SMA
Sell
Level
$1.34
Relative Strength Index (RSI14)
Sell
Level
45.14
ADX Line
Buy
Level
14.33
Williams %R
Neutral
Level
-43.2432
50-day SMA
Sell
Level
$1.52
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-8.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.262)
Sell
CA Score
(Annual)
Level (-2.3893)
Buy
Beneish M-Score
(Annual)
Level (-3.3623)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.8816)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
Stock Forecast FAQ
In the current month, SKIN has received 0 Buy ratings 7 Hold ratings, and 0 Sell ratings. The SKIN average analyst price target in the past 3 months is $1.58.
-
Where Will The Beauty Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that The Beauty Health share price will rise to $1.58 per share over the next 12 months.
-
What Do Analysts Say About The Beauty Health?
Analysts are divided on their view about The Beauty Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Beauty Health is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is The Beauty Health's Price Target?
The price target for The Beauty Health over the next 1-year time period is forecast to be $1.58 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is SKIN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for The Beauty Health is a Hold. 7 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SKIN?
You can purchase shares of The Beauty Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Beauty Health shares.
-
What Is The The Beauty Health Share Price Today?
The Beauty Health was last trading at $1.34 per share. This represents the most recent stock quote for The Beauty Health. Yesterday, The Beauty Health closed at $1.34 per share.
-
How To Buy The Beauty Health Stock Online?
In order to purchase The Beauty Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
29
UNF alert for Mar 27
UniFirst [UNF] is up 0.24% over the past day.
Sell
42
COCO alert for Mar 27
The Vita Coco [COCO] is down 11.03% over the past day.
Buy
91
EXOD alert for Mar 27
Exodus Movement [EXOD] is down 10.78% over the past day.
